Wednesday, 26 August 2026European Markets

LAVIDE HOLDING Stock Over 17% Down In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of LAVIDE HOLDING (AEX-Index: LVIDE.AS) dropped by a staggering 17.16% in 5 sessions from €0.34 to €0.28 at 17:08 EST on Monday, after four successive sessions in a row of losses. AEX-Index is rising 0.5% to €777.83, after five consecutive sessions in a row of gains.

LAVIDE HOLDING's last close was €0.28, 47.58% under its 52-week high of €0.54.

About LAVIDE HOLDING

Lavide Holding N.V. does not have significant operations. Previously, it was engaged in the provision of integrated information technology solutions for medium to large-sized companies and organizations. The company was formerly known as Qurius N.V. and changed its name to Lavide Holding N.V. in July 2013. Lavide Holding N.V. was incorporated in 1998 and is based in Sluis, the Netherlands.

Earnings Per Share

As for profitability, LAVIDE HOLDING has a trailing twelve months EPS of €-0.04.

Yearly Top and Bottom Value

LAVIDE HOLDING's stock is valued at €0.28 at 17:08 EST, way below its 52-week high of €0.54 and way above its 52-week low of €0.14.

Volume

Today's last reported volume for LAVIDE HOLDING is 894 which is 89.44% below its average volume of 5544.

Volatility

LAVIDE HOLDING's last week, last month's, and last quarter's current intraday variation average was a negative 4.86%, a positive 0.83%, and a positive 6.25%.

LAVIDE HOLDING's highest amplitude of average volatility was 4.86% (last week), 4.84% (last month), and 6.25% (last quarter).

More news about LAVIDE HOLDING (LVIDE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com